These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 24251546

  • 1. Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy.
    Töpfer M, Töllner K, Brandt C, Twele F, Bröer S, Löscher W.
    Eur J Neurosci; 2014 Feb; 39(4):673-87. PubMed ID: 24251546
    [Abstract] [Full Text] [Related]

  • 2. A novel prodrug-based strategy to increase effects of bumetanide in epilepsy.
    Töllner K, Brandt C, Töpfer M, Brunhofer G, Erker T, Gabriel M, Feit PW, Lindfors J, Kaila K, Löscher W.
    Ann Neurol; 2014 Apr; 75(4):550-62. PubMed ID: 24615913
    [Abstract] [Full Text] [Related]

  • 3. The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide.
    Töllner K, Brandt C, Römermann K, Löscher W.
    Eur J Pharmacol; 2015 Jan 05; 746():167-73. PubMed ID: 25449033
    [Abstract] [Full Text] [Related]

  • 4. Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy.
    Brandt C, Seja P, Töllner K, Römermann K, Hampel P, Kalesse M, Kipper A, Feit PW, Lykke K, Toft-Bertelsen TL, Paavilainen P, Spoljaric I, Puskarjov M, MacAulay N, Kaila K, Löscher W.
    Neuropharmacology; 2018 Dec 05; 143():186-204. PubMed ID: 30248303
    [Abstract] [Full Text] [Related]

  • 5. Heterogeneous brain distribution of bumetanide following systemic administration in rats.
    Löscher W, Gramer M, Römermann K.
    Biopharm Drug Dispos; 2024 Jun 05; 45(3):138-148. PubMed ID: 38823029
    [Abstract] [Full Text] [Related]

  • 6. The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia.
    Welzel B, Schmidt R, Kirchhoff L, Gramer M, Löscher W.
    Epilepsy Behav; 2023 Feb 05; 139():109057. PubMed ID: 36586153
    [Abstract] [Full Text] [Related]

  • 7. Bumetanide enhances phenobarbital efficacy in a neonatal seizure model.
    Dzhala VI, Brumback AC, Staley KJ.
    Ann Neurol; 2008 Feb 05; 63(2):222-35. PubMed ID: 17918265
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B.
    Hampel P, Römermann K, MacAulay N, Löscher W.
    Sci Rep; 2018 Jun 29; 8(1):9877. PubMed ID: 29959396
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain.
    Hampel P, Römermann K, Gramer M, Löscher W.
    Epilepsy Behav; 2021 Jan 29; 114(Pt A):107616. PubMed ID: 33279441
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.